Company intelligence / Profile preview

NSC Therapeutics

Austria or Switzerlandnsctherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

NSC Therapeutics is developing NSC001, a selective orthosteric M1 muscarinic agonist for neurodegenerative diseases. The compound has completed four phase 1 studies demonstrating safety and tolerability, and is entering a two-part phase 2a clinical trial in patients with mild to moderate Alzheimer’s disease. Preclinical data suggest potential disease-modifying effects on cognition and key pathological markers (Abeta, tau, alpha-synuclein), as well as modulation of neuroinflammation via TREM2[1][2][3].

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

NSC001

Phase 2

Indications: Alzheimer's disease, Parkinson's disease

Partnerships

NeurimmuneAlzheimer’s Drug Discovery Foundation (funding partner)

Beyond the preview

Go deeper on NSC Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NSC Therapeutics.

Explore the full profile